Heartcare Medical-B Surges 14% on Strong Profit Guidance and NMPA Acceptance of Novel Drug-Eluting Stent Application

Gelonghui January 21 | HeartCare-B (6609.HK) surged by 14.1% to HK$57.85 during the morning trading session today. HeartCare announced last night that the group expects to record revenue between approximately RMB 400 million and RMB 410 million for the fiscal year ending December 31, 2025, representing an increase of at least 43.9% compared to RMB 278 million for the fiscal year ending December 31, 2024. The group also anticipates reporting a pre-tax profit of approximately RMB 80 million during the reporting period, marking a significant increase from the pre-tax net loss of RMB 12 million for the fiscal year ending December 31, 2024.

On the same day, the company also announced that the registration application for its self-expanding intracranial drug-eluting stent developed by the group has been accepted by the National Medical Products Administration of the People's Republic of China. The self-expanding intracranial drug-eluting stent is used for the treatment of intracranial atherosclerotic stenosis, providing support and opening for narrowed and obstructed lumens, and can effectively prevent in-stent lumen restenosis. According to publicly available information, there are currently no similar products approved for marketing worldwide, and the company’s R&D progress for this type of product is at a leading level within the industry. (Gelonghui)